esmolol has been researched along with Atrioventricular Block in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hobai, IA | 1 |
| Aziz, PF; Pass, RH; Shah, MJ; Tanel, RE; Vetter, VL; Vogel, RL; Wieand, TS; Zelster, IJ | 1 |
2 other study(ies) available for esmolol and Atrioventricular Block
| Article | Year |
|---|---|
Atrioventricular block induced by indigo carmine.
Topics: Adjuvants, Anesthesia; Adrenergic Agents; Adrenergic beta-Antagonists; Anesthetics, Intravenous; Atrioventricular Block; Blood Pressure; Coloring Agents; Cystoscopy; Electrocardiography; Ephedrine; Female; Heart Rate; Humans; Indigo Carmine; Intraoperative Complications; Male; Metoprolol; Midazolam; Middle Aged; Muscarinic Antagonists; Propanolamines; Propofol; Prostatectomy | 2008 |
Congenital long QT syndrome and 2:1 atrioventricular block: an optimistic outcome in the current era.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrioventricular Block; Child; Child, Preschool; Cohort Studies; Defibrillators, Implantable; Female; Flecainide; Genotype; Humans; Infant; Infant, Newborn; Long QT Syndrome; Male; Mexiletine; Multivariate Analysis; Prognosis; Propanolamines; Propranolol; Retrospective Studies; Risk Assessment; Risk Factors; Torsades de Pointes; Treatment Outcome | 2010 |